News | November 10, 2021
India Pharmaceutical Market grows 5% in October 2021
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
_256_384.jpg)
Both parties are expected to invest a total of US $ 1 million to establish the brand
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Cipla has reported consolidated financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Subscribe To Our Newsletter & Stay Updated
